Cybin (CYBN.NE) announced that they will be using Alcohol Use Disorder (AUD) as the initial target indication for their proprietary psychedelic molecule, CYB003. To read full article: https://equity.guru/2021/04/26/cybin-cybn-ne-to-target-alcoholism-in-their-cyb003-clinical-studies/
Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
